Theravance Biopharma (TBPH) Other Non Operating Income (2014 - 2026)
Theravance Biopharma (TBPH) posted quarterly Other Non Operating Income of $3.0 million for Q1 2026, up 220.87% year-over-year from $939000.0 in Q1 2025, and down 17.2% quarter-over-quarter from $3.6 million in Q4 2025.
Theravance Biopharma (TBPH) Other Non Operating Income (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Other Non Operating Income for 13 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 220.87% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $12.2 million (up 179.25% YoY), while the FY2025 annual figure was $10.2 million, up 108.42% from the prior year.
- Other Non Operating Income slipped to $3.0 million in Q1 2026 per TBPH's latest filing, from $3.6 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $4.1 million in Q3 2025 and bottomed at -$7.9 million in Q4 2022.
- Historically, Other Non Operating Income has averaged $1.4 million across 5 years, with a median of $1.8 million in 2023.
- On a YoY basis, Other Non Operating Income climbed as much as 1761.45% in 2022 and fell as far as 2424.56% in 2022.
- Theravance Biopharma's Other Non Operating Income stood at -$7.9 million in 2022, then surged by 123.51% to $1.8 million in 2023, then sank by 51.06% to $904000.0 in 2024, then surged by 302.54% to $3.6 million in 2025, then slipped by 17.2% to $3.0 million in 2026.
- Business Quant data shows TBPH's Other Non Operating Income at $3.0 million in Q1 2026, $3.6 million in Q4 2025, and $4.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.49 Mn |
| Mar 31, 2026 | 3.01 Mn |
| Dec 31, 2025 | 3.64 Mn |
| Sep 30, 2025 | 4.14 Mn |
| Jun 30, 2025 | 1.46 Mn |
| Mar 31, 2025 | 939,000.00 |
| Dec 31, 2024 | 904,000.00 |
| Sep 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.43 Mn |
| Dec 31, 2023 | 1.85 Mn |
| Sep 30, 2023 | 1.79 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 2.98 Mn |
| Dec 31, 2022 | -7.86 Mn |
| Sep 30, 2022 | 2.76 Mn |
| Jun 30, 2022 | 2.44 Mn |
| Mar 31, 2022 | -375,000.00 |
| Dec 31, 2021 | 338,000.00 |
| Sep 30, 2021 | -166,000.00 |